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Abstract 
Although aldosterone plays an essential role in the control of electrolyte and body fluid homeostasis, it 
also exerts certain pathological effects on the kidney. Several previous studies have attempted to examine 
these deleterious effects. However, the majority of those studies were done using various injury models, 
high salt treatment and/or mineralocorticoid administration by which the kidney change observed not only 
due to aldosterone but also due to prior injury, salt and hypertension. In the present study, we performed 
study to investigate aldosterone pathological effect on the kidney using mice model with high level of 
endogenous aldosterone. We used cryptochrome-null (Cry 1, 2 double knockout (DKO)) mice that are 
characterized by high aldosterone levels and low plasma renin activity, and indicated that even under 
conditions of normal salt exposure, these mice showed an increase in albumin excretion and kidney 
tubular injury, a decrease of nephrin expression, and an increase in the production of reactive oxygen 
species in the absence of hypertension. Exposure to high levels of salt exacerbated the kidney damage 
observed in these mice. Moreover, we noted that decreasing the blood pressure without blocking the 
aldosterone action did not provide beneficial effects to the kidney in high-salt-treated Cry 1, 2 DKO mice. 
Thus, our findings support the hypothesis that aldosterone causes deleterious effects on the kidney 
independently of high-salt exposure and high blood pressure.  
Keywords: aldosterone, blood pressure, kidney, salt. 
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Introduction 
Aldosterone is a mineralocorticoid hormone that is produced in the cortex of the adrenal glands. In 
physiological conditions, its binding with specific intracellular mineralocorticoid receptors (MRs) in the 
distal nephron regulates electrolytes and water homeostasis.1 Thus, aldosterone regulates blood volume 
and blood pressure.2 However, aldosterone also contributes to the development of kidney damage, as 
reported in several studies.3,4 Primary aldosteronism, which is characterized by high plasma aldosterone 
levels and low renin activity, is often correlated with an increased risk of kidney damage.5  
Remnant kidney model in animal with elevated plasma aldosterone level showed hypertension and 
proteinuria.6 In another study with increase of mineralocorticoid levels following deoxycorticosterone 
acetate (DOCA) administration and high-salt treatment in rats subjected to unilateral nephrectomy has 
been found to induce hypertension, peritubular capillary loss, and tubular interstitial fibrosis.7 Moreover 
in rats treated with salt and aldosterone for 28 days, severe kidney damage and hypertension were 
observed.8 By using those models, hypertension role in the development of kidney damage could not be 
ruled out. Studies on several animal models of kidney injury have indicated that the administration of an 
MR blocker could ameliorate kidney damage independent of blood pressure.9, 10 To further elucidate the 
aldosterone effect towards the kidney independent of blood pressure, some studies have been performed 
by decreasing the blood pressure without interfering with the aldosterone effect by using hydralazine 
treatment11, whereas other studies have involved the administration of a non-hypotensive dose of an MR 
blocker12 or administration of low-dose aldosterone.13 Even many aldosterone induced renal pathology 
studies have been done but most of them are using injury models such as subtotal renal ablation and 
unilateral nephrectomy, mineralocorticoid administration, high salt treatment or combination of these 
methods by which the aldosterone pathological effect towards the kidney could not be distinguished 
clearly with the previously existed injury, salt and hypertension.  
To study aldosterone induced kidney damage in the absence of prior kidney manipulation, high salt 
treatment and/or mineralocorticoid administration, we used Cry 1, 2 DKO mice. Cryptochrome is known 
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to regulate the circadian rhythm.14 Cry 1, 2 DKO mice show increased mRNA expression and protein 
levels of 3β hydroxysteroid dehydrogenase, the enzyme involved in the aldosterone synthesis. The 
enzyme is expressed particularly in the zona glomerulosa where the production of aldosterone is known to 
exclusively take place. Thus, Cry 1, 2 DKO mice present with high aldosterone levels but low plasma 
renin activity.15 
Methods 
Animal experiments 
In the present study, we used cryptochrome-null (Cry 1, 2 DKO) mice, which characteristically show high 
plasma aldosterone levels and suppressed renin activity.15 The development of Cry 1, 2 DKO mice has 
been described previously.16 During the course of the study, all the mice were maintained at a stable 
environmental temperature with a 12-hour light and dark cycle and had free access to water and chow. All 
the experiment protocols were performed based on the animal experiment guidelines of Kobe University, 
Kobe, Japan. 
We used Cry 1, 2 DKO mice and wild-type littermates as the controls. We divided 12-week-old male 
mice into the following 6 groups: wild-type mice treated with normal salt (WTNS; n = 17), wild-type 
mice receiving high-salt treatment (WTHS; n = 16), Cry 1, 2 DKO mice receiving normal salt treatment 
(CRYNS; n = 13), Cry 1, 2 DKO mice receiving high-salt treatment (CRYHS; n = 20), Cry 1, 2 DKO 
mice receiving high-salt and spironolactone treatment (CRYSPI; n = 13), and Cry 1, 2 DKO mice 
receiving high-salt and hydralazine treatment (CRYHYD; n = 6). All the mice underwent the respective 
treatments for 32 weeks. Normal salt chow refers to 0.2% NaCl content in the chow, whereas high-salt 
chow refers to 3.15% NaCl content in the chow and 1% NaCl and 0.2% KCl in the drinking water. 
Spironolactone or hydralazine was administered in the drinking water. The doses of spironolactone 
(Sigma-Aldrich, St. Louis, MO) and hydralazine (Sigma-Aldrich) were 6mg/kg body weight/day and 
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25mg/kg body weight/day, respectively.  Spironolactone was dissolved in ethanol and then diluted in 
drinking water. 
Blood pressure measurement 
Blood pressure was determined in conscious trained mice using a non-invasive computerized automated 
tail-cuff system (BP-98A, Softron, Tokyo, Japan). The average value of 10 measurements was used for 
data analysis.  
Blood and urine biochemical analysis 
Blood was obtained for biochemical analysis after 32 weeks of treatment by cardiac puncture before the 
mice were sacrificed. A 24-hour urine collection was performed using metabolic cages 1 day before the 
mice were sacrificed. Creatinine concentrations in the serum and urine were measured using an enzymatic 
assay (Nescoat VLII CRE Kit; Alfresa Pharma Corp, Osaka, Japan). A commercially available enzyme-
linked immunosorbent assay kit was used to measure urine albumin (Bethyl Laboratories, Inc, 
Montgomery, TX) according to the manufacturer’s instructions. Serum aldosterone was measured using a 
commercially available enzyme immunoassay kit (Enzo Life Sciences Inc, Plymouth Meeting, PA) 
according to the protocol described by the manufacturer. Serum and urine electrolyte was measured using 
ion selective electrode (ISE) and calculated using the Nernst equation. 
Gene expression 
The total RNAs from the removed kidney were extracted using RNAIsoPlus (TaKaRa, Dalian, China). 
Reverse transcription was performed using ReverTra Ace (Toyobo, Osaka, Japan) according to the 
manufacturer’s instructions. The quantification of the gene expression levels of renin, the MR, 11BHSD2, 
nephrin, and G6PD was performed using the Thunderbird SYBR qPCR Mix (Toyobo, Osaka, Japan) 
according to the protocol described by the manufacturer. Primers used in this study were as follows: renin 
(forward: 5′ATGAAGGGGGTGTCTGTGGGGTC3′; reverse: 
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5′ATGTCGGGGAGGGTGGGCACCTG3′), MR (forward: 5′GGAAACCAAAGGCTACCACA3′; 
reverse: 5′AGTGTGGAGGACCTGTGACC3’), 11BHSD2 (forward: 
5′TTTGGTGCACTTGAGCTGAC3′; reverse: 5′GGTATGGCATGTCTCCTGCT3′), nephrin (forward: 
5′ACTACGCCCTCTTCAAATGCA3′; reverse: 5′TCGAGGGCCTCATACCTGAT3′), G6PD (forward: 
5′GTTAAATGGGCCAGCGAAG3′; reverse: 5′CCTGCTCTGCCATGATGTTT3′), and glyceraldehyde 
3-phosphate dehydrogenase (forward: 5′TGTGTCCGTCGTGGATCTGA3′; reverse: 
5′TTGCTGTTGAAGTCGCAGGAG3).  
Histopathology quantification 
The kidneys of the mice were obtained and fixed with 4% paraformaldehyde overnight at room 
temperature before they were processed into paraffin. Thereafter, 4-µm sectioned samples were used for 
periodic acid-Schiff (PAS) staining and Sirius red staining. Tubular injury was assessed at 200× 
magnification in samples from each group that were stained with PAS. Tubular injury was assessed using 
15 non-overlapping fields of view. Tubular injury was defined as the presence of tubular epithelial 
swelling, tubular epithelial vacuolization, tubular necrosis, and loss of brush border, and was categorized 
into 5 grades from 0 to 4, as described previously.17 Glomerulosclerosis index quantification was 
performed using 20 PAS-stained glomeruli. The glomeruli were scored on a 0−4 scale for 
glomerulosclerosis, as described previously.18 The scores for all glomeruli were averaged and presented as 
the glomerulosclerosis index. Tubular interstitial fibrosis quantification was performed using 20 Sirius 
red-stained sections at 200× magnification. The fibrosis area was quantified using ImageJ software (US 
National Institutes of Health, Bethesda, MD) and presented as the percentage area of fibrosis. Nephrin 
staining was performed on cryosections. Briefly, sectioned slides were incubated with an antibody against 
nephrin (Progen Biotechnik GmbH, Heidelberg, Germany) at 100× dilution overnight at 4°C. Nephrin 
expression was presented as the percentage of the entire glomerulus area that was positive for nephrin. 
Fifteen glomeruli were assessed for nephrin expression using the ImageJ software.  
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Assessment of reactive oxygen species production 
The assessment of ROS production was performed by cryosections staining with dihydroethidium (DHE). 
Briefly, cryosections were incubated with 5-µM DHE in dimethyl sulfoxide at 37°C for 30 minutes. The 
quantification of DHE intensity was performed using 15 visual fields at 200× magnification. 
Statistical analyses 
All data are presented as mean ± SEM. We have assumed that the groups were not normally distributed. 
We therefore performed statistical analysis of multiple groups using the non-parametric Kruskal–Wallis 
test, followed by Mann–Whitney U-test between two groups. A P value of <0.05 was considered 
significant. 
Results 
Serum aldosterone and renin gene expression level 
Serum aldosterone levels were significantly greater in Cry 1, 2 DKO mice compared with wild-type mice. 
High levels of serum aldosterone in Cry 1, 2 DKO mice were persistent even under high-salt treatment, 
whereas serum aldosterone levels in wild-type mice were significantly decreased following high-salt 
treatment (Figure 1A). To assess whether aldosterone production is independent of renin gene expression, 
we examined renin gene expression in the whole kidney of Cry 1, 2 DKO and wild-type mice. We noted 
that renin gene expression in the whole kidney was similar among the groups (Figure 1B). The 
aldosterone receptor (MR) expression in the whole kidney was also similar among the groups. Since MRs 
are nonspecific receptors and their specificity is determined by 11β hydroxysteroid dehydrogenase type 2 
(11BHSD2),19 we measured 11BHSD2 expression in the whole kidney as well. However, we did not note 
any difference in 11BHSD2 expression among all groups (Figure 1C and 1D).  
Blood pressure examination 
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Blood pressure was similar between the Cry 1, 2 DKO mice receiving normal salt treatment (CRYNS) 
and wild-type mice treated with normal salt (WTNS) groups. Under high-salt treatment, the systolic blood 
pressure in the Cry 1, 2 DKO mice receiving high-salt treatment (CRYHS) group increased significantly. 
Moreover, spironolactone treatment did not decrease the blood pressure in the Cry 1, 2 DKO mice 
receiving high-salt and spironolactone treatment (CRYSPI) group. However, hydralazine treatment 
significantly decreased the blood pressure in the Cry 1, 2 DKO mice receiving high-salt and hydralazine 
treatment (CRYHYD) group (Figure 2).  
Blood and urine biochemical analysis 
Creatinine clearance levels were similar between Cry 1, 2 DKO and wild-type mice receiving normal salt 
treatment (Figure 3A). High-salt treatment increased the creatinine clearance in Cry 1, 2 DKO mice but 
not in wild-type mice. Spironolactone or hydralazine treatment in high-salt-treated Cry 1, 2 DKO mice 
did not decrease the creatinine clearance. To further examine the effect of hyperaldosteronism on kidney 
function, we assessed the urinary albumin levels. Under normal salt treatment, urinary albumin levels 
were significantly higher in Cry 1, 2 DKO mice compared with wild-type mice (Figure 3B). High-salt 
treatment in Cry 1, 2 DKO mice further increased urinary albumin excretion. However, treatment with 
spironolactone, but not hydralazine, decreased urinary albumin excretion. Sodium and potassium 
concentration both in serum and urine were the same between Cry 1, 2 DKO and wild type mice under the 
same treatment. Treatment with high salt and spironolactone or hydralazine in Cry 1, 2 DKO and WT 
mice induced no statistically significant difference in serum sodium and potassium concentration. High 
salt treatment increased the urine sodium and potassium concentration both in Cry 1, 2 DKO and wild 
type mice. Treatment with high salt and spironolactone or hydralazine in Cry 1, 2 DKO mice also resulted 
in the increase of urine sodium and potassium concentration (Figure 3C-F). 
Kidney histology assessment 
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Kidney tubular injury and kidney fibrosis were measured in the tubular area of the kidney by PAS 
staining and Sirius red staining respectively (Figure 4A).  Glomerulosclerosis was measured in 
glomerular area of the kidney using PAS staining (Figure 4A). Kidney tubular injury was observed in the 
CRYNS group but not in the WTNS group (Figure 4B). The mice in the CRYHS group exhibited more 
severe kidney tubular injury compared with mice in the wild-type mice receiving high-salt treatment 
(WTHS) and CRYNS groups. Moreover, spironolactone treatment ameliorated kidney tubular injury in 
the CRYSPI group, whereas hydralazine treatment did not improve kidney tubular injury in the 
CRYHYD group. Examination of glomerulosclerosis and quantification of tubular interstitial fibrosis 
were similar among the treatment groups (Figure 4C and 4D). Nephrin expression in the glomerular area 
was analyzed by immunostaining (Figure 5A). Mice in the CRYNS group showed lower levels of nephrin 
expression compared to those in the WTNS group (Figure 5B and 5C). The level of nephrin expression in 
the CRYHS group was lower compared with those in the WTHS and CRYNS groups. However, 
treatment with spironolactone, but not hydralazine, improved the levels of nephrin expression in high-
salt-treated Cry 1, 2 DKO mice. 
Reactive oxygen species (ROS) production 
Production of ROS in the kidney was examined using DHE staining depicted in figure 6A. We observed 
significantly higher levels of ROS in the CRYNS group compared to the WTNS group. Mice in the 
CRYHS group showed a further increase in ROS production in the kidney. Spironolactone treatment in 
high-salt-treated Cry 1, 2 DKO mice caused a decrease in ROS production, whereas hydralazine treatment 
did not (Figure 6B). To further examine the cause of the increased ROS production, we examined the 
expression of glucose-6-phosphate dehydrogenase (G6PD). The levels of G6PD expression decreased in 
the CRYNS and CRYHS groups compared to the WTNS and WTHS groups, respectively. Treatment 
with spironolactone, but not hydralazine, improved the levels of G6PD expression in high-salt-treated Cry 
1, 2 DKO mice (Figure 6C). 
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Discussion 
In the present study, we demonstrated chronic hyperaldosteronism pathological effect towards the kidney 
independent of high salt treatment and hypertension in the Cry 1, 2 DKO mice. Our model showed that 
even under normal salt treatment, chronic hyperaldosteronism resulted in albuminuria, tubular injury, 
decreased nephrin expression, and increased ROS production in the absence of hypertension. Notably, the 
pathological processes due to the hyperaldosteronism have taken place after a long follow-up period (32 
weeks). We further confirmed that the high-salt exposure in the previous condition induced more severe 
kidney damage compared with that observed in hyperaldosteronism case alone. Finally, we also 
demonstrated that kidney damage induced by hyperaldosteronism and high-salt exposure is independent 
of blood pressure. 
Despite the high plasma aldosterone levels, the Cry 1, 2 DKO mice under normal salt treatment showed 
no different of blood pressure and serum potassium level compared with those on wild type mice under 
the same treatment. Although hyperaldosteronism is frequently associated with hypertension and 
hypokalemia, normotensive or normokalemic patients with hyperaldosteronism have also been 
reported.20-22 Therefore, hypertension should not be used as a prerequisite for the diagnosis of primary 
aldosteronism.20	 It is also suggested that normokalemia should not exclude the possibility of primary 
hyperaldosteronism.23 
We noted that the Cry 1, 2 DKO mice, in the present study, developed albuminuria following normal salt 
treatment and in the absence of elevated blood pressure. Aldosterone exerts its effect by binding with 
MRs. In the kidney, MRs are expressed mainly in the distal tubules and collecting ducts.24 A lower 
expression of MRs have been reported in glomeruli, particularly in mesangial cells25 and podocytes26 in 
which aldosterone may act directly. In unilateral nephrectomized rats receiving aldosterone and high-salt 
treatment, proteinuria was found to be associated with a decrease in the levels of nephrin, which is a 
podocyte-related protein.26 Nephrin is expressed specifically in the slit diaphragm of podocytes and 
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therefore plays an important role in the function of the glomerular filtration barrier.27 In the present study, 
we observed that Cry 1, 2 DKO mice showed a decrease in the levels of nephrin expression. Therefore, 
we suggest that a decrease in the levels of nephrin expression in Cry 1, 2 DKO mice results in the 
disruption of the glomerular filtration barrier, and thus influences, at least in part, the urinary albumin 
level.  
In our study, Cry 1, 2 DKO mice characterized by hyperaldosteronism showed increased kidney ROS 
production in the absence of high-salt exposure, which is consistent with the findings of previous 
studies.28, 29 Administration of the ROS detoxifier agent tempol to uninephrectomized rats receiving high-
salt treatment and aldosterone has been reported to ameliorate kidney damage11, indicating that ROS 
production might be one of the responsible factors for aldosterone-induced kidney damage. The results in 
the present study suggest that this applies to cases with only hyperaldosteronism as well. In addition, we 
noted that G6PD expression decreased in Cry 1, 2 DKO mice. G6PD is the first enzyme in the pentose 
phosphate pathway, which is an important source of NADPH (Nicotinamide Adenine Dinucleotide 
Phosphate).29A previous study involving aldosterone- and salt-treated mice indicated a decrease in the 
expression and activity of G6PD in the aorta; this promotes increased ROS accumulation due to the 
failure in maintaining the production of NADPH that is an important intracellular reducing equivalent.30 
G6PD deficiency in mice also reportedly results in increased renal oxidative stress and urinary albumin 
levels.29 Thus, the decrease in the expression levels of G6PD in Cry 1, 2 DKO mice may play a role in the 
increase in ROS production and urinary albumin levels. 
Compared with animal models combining unilateral nephrectomy as well as high-salt and 
mineralocorticoid exposure, wherein a relatively short-term treatment (4–8 weeks) produced severe 
kidney damage including glomerulosclerosis and kidney fibrosis8, 12, the kidney damage observed in the 
normal salt-treated Cry 1, 2 DKO mice over 32 weeks was less severe. Moreover, even after 32 weeks of 
high-salt treatment, the Cry 1, 2 DKO mice did not develop glomerulosclerosis or interstitial fibrosis. 
Based on these observations, we cannot rule out the fact that chronic endogenous hyperaldosteronism 
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may have induced adaptive mechanisms, which could have limited the deleterious effects of aldosterone. 
These results may reflect clinical findings in primary aldosteronism patients who often present with 
microalbuminuria and increased glomerular filtration rate (GFR)31 that can be successfully treated either 
by adrenalectomy or MR blocker treatment.32-34 Moreover, severe kidney damage is believed to develop 
only after several years.35 
In the present study, we confirmed that aldosterone combined with high-salt treatment can induce severe 
kidney damage. High-salt exposure has been proved to exert pathological effects on the kidney. In rats 
with renal transplantation, an elevated salt intake (8% NaCl) induces albuminuria, glomerulosclerosis, 
and tubulointerstitial injury.36 In a rat model of metabolic syndrome, high-salt treatment for 4 weeks also 
promotes hypertension, proteinuria, and kidney damage.37 In a genetic rat model with lower nephron 
density that received high-salt treatment for 6 weeks, increased blood pressure and albuminuria were 
observed.38 Interestingly, the pathological effect of salt is related to MR activation. A previous study 
showed that MR blockers could ameliorate hypertension, proteinuria, and kidney injury in unilateral 
nephrectomized rats receiving 4 weeks of high-salt treatment.39 Another study in salt-sensitive Dahl rats 
receiving high-salt treatment indicated the presence of increased blood pressure, albuminuria, kidney 
damage, and impaired MR signaling in the kidney.40 Therefore, we suggest that kidney damage in high-
salt-treated Cry 1, 2 DKO mice was caused by MR activation due to both hyperaldosteronism and high-
salt exposure.  
High-salt-induced kidney damage in Cry 1, 2 DKO mice was independent of blood pressure. We used 
low-dose spironolactone (an MR blocker) to inhibit the effect of aldosterone without decreasing blood 
pressure. It has been reported previously that the administration of spironolactone at a dose of 6-mg/kg 
body weight/day did not decrease blood pressure in an angiotensin II-treated mice model. Moreover this 
low dose of spironolactone did not decrease urinary potassium level as already observed.41 Spironolactone 
treatment decreased the urinary albumin level, nephrin expression, and ROS production but did not 
change the creatinine clearance in the CRYHS group. The increase in creatinine clearance in cases of 
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hyperaldosteronism and high-salt exposure as observed in Cry 1, 2 DKO mice may be a result of a 
functional adaptation, which is induced by increased sodium reabsorption and body fluid volume, and 
may lead to hypertension, an increase in renal perfusion pressure, suppression of renin activity, and a 
decrease in intrarenal vascular resistance.35 In WT mice, the creatinine clearance did not increase because 
both blood pressure and aldosterone levels remained stable on high salt diet. Since the dose of 
spironolactone used in the present study did not result in a decrease in the blood pressure in Cry 1, 2 DKO 
mice, we suggest that renal perfusion and intrarenal vascular resistance did not change as well, which 
would explain the stable creatinine clearance level. To further analyze the effect of aldosterone on the 
development of kidney damage independent of blood pressure, we administered a direct vasodilator, 
hydralazine. Hydralazine decreases blood pressure by inducing arterial smooth muscle relaxation.42 
Therefore the effect in this group is representative of a decrease in blood pressure without any 
interference in the aldosterone-MR interaction. Despite the decrease in blood pressure, treatment with 
hydralazine in high-salt-treated Cry 1, 2 DKO mice did not improve creatinine clearance, albuminuria, 
nephrin expression, and ROS production. In another study of rats treated with aldosterone, 1% NaCl, and 
hydralazine for 4 weeks, a similar result was noted; in this study, hydralazine treatment decreased blood 
pressure but did not change the creatinine clearance value, albuminuria, kidney sclerosis, or ROS 
production.11 In certain normal, hypertensive, and congestive heart failure patients, hydralazine does not 
appear to influence GFR.43, 44 The fact that the change in renal plasma flow produced by a vasodilator did 
not change the GFR indicates the presence of a filtration pressure disequilibrium.43 Therefore, given the 
fact that treatment with spironolactone, but not hydralazine, prevented kidney damage, we suggest that 
the deleterious effects of salt and hyperaldosteronism on the kidney were specifically due to MR 
activation. 
Considering the role of cryptochromes on the circadian rhythm, the effect of cryptochrome deletion in 
Cry 1, 2 DKO mice cannot be disregarded. The increase in urinary albumin levels, decrease in nephrin 
expression, and increase in ROS production in high-salt-treated CRYHS mice were inhibited by 
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spironolactone treatment. Thus, we assumed that the kidney damage that developed in the Cry 1, 2 DKO 
mice was related to hyperaldosteronism.  
Finally, the levels of nephrin expression and ROS production in the mice in the spironolactone-treated 
group were better than those in the CRYNS group and comparable to those in the WTNS group. Thus, in 
addition to the inhibition of the combined effect of hyperaldosteronism and salt, spironolactone may also 
suppress the effect of hyperaldosteronism alone.  
In conclusion, our study demonstrated that the deleterious effects of aldosterone on the kidney might be 
independent of high-salt exposure and high blood pressure, even though high-salt treatment exacerbates 
these effects. Based on our findings, we suggest that controlling blood pressure may not be sufficient to 
protect the kidney in primary aldosteronism; however, the direct blocking of aldosterone may be 
sufficient to protect the kidney in such cases. 
Disclosure 
Authors declared no competing interest. 
Acknowledgments 
This study were supported by following grants:   
• The Science Research Promotion Fund from The Promotion and Mutual Aid Corporation for 
Private Schools of Japan (to N.E). 
• Faculty Resources Grant, Kobe University, the Global COE Program, Global Center of 
Excellence for Education and Research on Signal Transduction Medicine in the Coming 
Generation from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of 
Japan (to D.AAN). 
 
	   16	  
References 
1. Porter GA, Edelman IS. The Action of aldosterone and related corticosteroids on sodium transport 
across the toad bladder. J Clin Invest. 1964; 43: 611–620 
2. Connell JMC, Davies E. The new biology of aldosterone. J Endocrinol.2005; 186: 1–20. 
3. Remuzzi G, Cattaneo D, Perico N. The aggravating mechanisms of aldosterone on kidney 
fibrosis. J Am Soc Nephrol. 2008; 19: 1459–1462.  
4. Fan YY, Kohno H, Hitomi H, Kitada K, Fujisawa Y, Yatabe J, Felder RA, Ohsaki H, Rafiq K, 
Sherajee SJ, Noma T, NIshiyama A, Nakano D. Aldosterone/mineralocorticoid receptor 
stimulation induces cellular senescence in the kidney. Endocrinology. 2011; 152: 680-688. 
5. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an 
analysis of 145 cases. Am J Surg. 1964; 107: 159-172. 
6. Greene EL, Kren S, Hotetter TH. Role of aldosterone in the remnant kidney model in the rat. J 
Clin Invest. 1996; 98: 1063-1068. 
7. Iwazu Y, Muto S, Fujisawa G, Nakazawa E, Okada K, Ishibasi S, Kusano E. Spironolactone 
suppresses peritubular capillary loss and prevents deoxycorticosterone acetate/salt-induced 
tubulointerstitial fibrosis.  Hypertension. 2008; 51: 749-754. 
8. Blasi ER, Rocha R, Rudolp AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces 
renal inflammation in hypertensive rats. Kidney Int. 2003; 63: 1791-1800. 
9. Krammer AB, van der Meulen EF, Hamming I, van Goor H, Navis G. Effect of combining ACE 
inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. 
Kidney Int. 2007; 71: 417-424. 
	   17	  
10. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK. 
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.  Endocrinology. 2000; 141: 
3871-3878.  
11. Queisser N, Amann K, Hey V, Habib SL, Schupp N. Blood pressure has only minor influence on 
aldosterone-induced oxidative stress and DNA damage in vivo. Free Radic Biol Med. 2013; 54: 
17-25. 
12. Klanke B, Cordasic N, Hartner A, Schmieder RE, Veelken R, Hilgers KF. Blood pressure versus 
direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension. 
Nephrol dial transplant. 2008; 23: 3456-3463. 
13. Brem AS, Morris DJ, Ge Y, Dworkin L, Tolbert E, Gong R. Direct fibrogenic effects of 
aldosterone on normotensive kidney: an effect modified by 11-HSD activity. Am J Physiol Renal 
Physiol. 2010; 298: F1178-1187. 
14. Sancar A. Regulation of the mammalian circardian clock by cryptochrome. J Biol Chem. 2004; 
279: 34079-34082. 
15. Doi M, Takahashi Y, Komatsu R, Yamazaki F, Yamada H, Haraguchi S, Emoto N, Okuno Y, 
Tsujimoto G, Kanematsu A, Ogawa O, Todo T, Tsutsui K, van der Horst GT, Okamura H. Salt-
sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal 
Hsd3b6. Nat Med. 2010; 16: 67–74. 
16. Vitaterna MH, Selby CP, Todo T, Niwa H, Thompson C, Fruechte EM, Hitomo K, Thresher RJ, 
Ishikawa T, Miyazaki J, Takahashi JS, Sancar A. Differential regulation of mammalian period 
genes and circardian rhythmicity by cryptochromes 1 and 2. Proc Natl Acad Sci U S A. 1999; 96: 
12114-12119.  
	   18	  
17. Fan H, Yang HC, You L, Wang YY, He WJ, Hao CM. The histone deacetylase, SIRT1, 
contributes to the resistance of young mice to ischemia/reperfusion-induced acute kidney injury. 
Kidney Int. 2013; 83: 404-413. 
18. Takagi N, Tanizawa T, Kon V, Fogo AB, Ichikawa I, Ma J. Mineralocorticoid receptor blocker 
protects against podocyte-dependent glomerulosclerosis. Nephron Extra. 2012; 2: 17-26. 
19. Funder JW. Mineralocorticoid receptors and cardiovascular damage: it's not just aldosterone. 
Hypertension. 2006; 47:634–635.  
20. Matsunaga M, Hara A, Song TS, Hashimoto M, Tamori S, Ogawa K, Morimoto K, Pak CH, 
Kawai C, Yoshida O. Asymptomatic normotensive primary aldosteronism : case report. 
Hypertension. 1983; 2: 240-243. 
21. Nishimiya T, Kikuchi K, Oimatsu H, Ota S, Nakamura Y, Shimamoto K, Iimura O. A case of 
normotensive primary aldosteronism-comparison with 13 previously experienced cases with 
hypertension. Endocrinal Jpn. 1984; 2: 159-164. 
22. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF Jr. Prevalence of primary aldosteronism 
among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab. 2000; 85: 2854-2859. 
23. Shargorodsky M, Zimlichman R. Primary aldosteronism: the most frequent form of secondary 
hypertension. Isr Med Assoc J. 2002; 4: 32-33. 
24. Lombès M, Farman N, Oblin ME, Baulieu EE, Bonvalet JP, Erlanger BF, Gasc JM. 
Immunohistochemical localization of renal mineralocorticoid receptor by using an anti-idiotypic 
antibody that is an internal image of aldosterone. Proc Natl Acad Sci U S A. 1990; 87: 1086-1088. 
25. Nishiyama A, Yao L, Fan Y, Kyaw M, Kataoka N, Hashimoto K, Nagai Y, Nakamura E, 
Yoshizumi M, Shokoji T, Kimura S, Kiyomoto H, Tsujioka K, Kohno M, Tamaki T, Kajiya F, 
	   19	  
Abe Y. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell 
proliferation and deformability. Hypertension. 2005; 45: 710-716. 
26. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: 
roles of oxidative stress and sgk1. Hypertension. 2007; 49: 355-364. 
27. Ruotsalainen V, Ljungberg P, Wartiovaara J, Lenkkeri U, Kestila M, Jalanko H, Holmberg C, 
Tryggvason K. Nephrin is specifically located at the slit diaphragm of glomerular podocytes. 
PNAS. 1999; 96: 7962-7967. 
28. Xu Y, Zhang Z, Hu J, Stillman IE, Leopold JA, Handy DE, Loscalzo J, Stanton RC. Glucose-6-
phosphate dehydrogenase-deficient mice have increased renal oxidative stress and increased 
albuminuria. FASEB J. 2010; 24: 609-616. 
29. Yoshida K, Kim-Mitsuyama S, Wake R, Izumiya Y, Yukimura T, Ueda M, Yoshiyama M, Iwao H. 
Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via 
oxidative stress. Hypertens Res. 2005; 28: 447– 455. 
30. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Loscalzo J. 
Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. 
Nat Med. 2007; 13: 189-197. 
31. Sechi LA, Di Fabio A, Bazzocchi M, Uzzau A, Catena C. Intrarenal hemodynamics in primary 
aldosteronism before and after treatment. J Clin Endocrinol Metab. 2009; 1191-1197. 
32. Kok KY, Yapp SK. Laparoscopic adrenal sparing surgery for primary hyperaldsteronism due to 
aldosterone producing adenoma. Surg Endosc. 2002; 1: 108-1011. 
33. Fourkiotis V, Vonend O, Diederich S, Fischer E, Lang K, Endress S, Beuschlein F, Willenberg HS, 
Rump LC, Allolio B, Reincke M, Quinkler M; Mephisto Study Group. Effectiveness of eplerenone 
	   20	  
or spironolactone treatment in preserving renal function in primary aldosteronism. Eur J 
ENdocrinol. 2012; 168: 75-81. 
34. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C. Long term renal 
outcomes in patients with primary aldosteronism. JAMA. 2006; 295: 2638-2645. 
35. Catena C, Colussi GL, Sechi AL. Kidney in primary aldosteronism: key determinant of treatment 
outcome. World J Hypertens. 2012; 2: 1-6. 
36. Sanders PW, Gibbs CL, Akhi KM, MacMillan-Crow LA, Zinn KR, Chen YF, Young CJ, 
Thompson JA. Increased dietary salt accelerates chronic allograft nephropathy in rats. Kidney Int. 
2001; 59: 1149-1157. 
37. Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T. Salt-induced nephropathy in obese 
spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role 
of oxidative stress. Hypertension. 2007; 50: 877-883. 
38. Kreutz R, Kovacevic L, Schulz A, Rothermund L, Ketteler M, Paul M. Effect of high NaCl diet on 
spontaneous hypertension in a genetic rat model with reduced nephron number. J Hypertens. 2000; 
18: 777-782. 
39. Kawarazaki H, Ando K, Shibata S, Muraoka K, Fujita M, Kawarasaki C, Fujita T. 
Mineralocorticoid receptor-Rac1 activation and oxidative stress play major roles in salt induced 
hypertension and kidney injury in prepubertal rats. J Hypertens. 2012; 30: 1977-1985. 
40. Shibata S, Mu S, Karawazaki H, Muraoka K, Ishizawa K, Yoshida S, Kawarazaki W, Takeuchi M, 
Ayuzawa N, Miyoshi J, Takai Y, Ishikawa A, Shimosawa T, Ando K, Nagase M, Fujita T. Rac1 
GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid 
receptor dependent pathway. J Clin Invest. 2011; 121: 3233-3243. 
	   21	  
41. Luther JM, Luo P, Wang Z, Cohen SE, Kim HS, Fogo AB, Brown NJ. Aldosterone deficiency and 
mineralocorticoid receptor antagonism prevent angiotensin II- induced cardiac, renal and vascular 
injury. Kidney Int. 2012; 82: 643-651. 
42. Ebeiqbe AB, Aloamaka CP. Mechanism of hydralazine-induced relaxation of arterial smooth 
muscle. Cardiovasc Res. 1985; 19: 400-405. 
43. Wilkinson EL, Backman H, Hecht HH. Cardiovascular and renal adjustment to hypotensive agents. 
Circulation. 1952; 31: 872-879. 
44. Cogen JJ, Humphreys MH, Carlson CJ, Rapaport E. Renal effects of nitroprusside and hydralazine 
in patients with congestive heart failure. Circulation. 1980; 61:316-323. 
 
 
 
 
 
 
 
 
 
 
 
	   22	  
Figure Legends 
 
 
Figure 1: Serum aldosterone concentration (A) and renin (B), mineralocorticoid receptor (MR) (C), 
and 11 beta hydroxysteroid dehydrogenase type 2 (11BHSD2) (D) mRNA expression. Serum 
aldosterone concentration measurement was performed in 5–9 mice. (B, C, and D) The graphs represent 
the ratio between mRNA expression normalized to the expression of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) mRNA in the whole kidney (n = 4). Data are presented as mean ± SEM. *P < 
0.05 using Mann–Whitney U test. 
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Figure 2: Systolic blood pressure measured in conscious mice using the tail-cuff method. Data are 
presented as mean ± SEM. n = 6–14. *P < 0.05 using Mann–Whitney U test. 
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Figure 3: Creatinine clearance (A), albuminuria (B), serum potassium level (C), serum sodium level 
(D), urine potassium level (E), urine sodium level (F) of 32 week treated mice. Data are presented as 
mean ± SEM. n = 6–13. *P < 0.05 using Mann–Whitney U test. 
 
 
 
Figure 4: Representative pictures of periodic acid-Schiff (PAS) staining of the tubular area, Sirius 
red staining of tubular area and PAS staining of the glomerular area (A). The graphs represent the 
quantification of the tubular injury score (B), glomerulosclerosis (C), and tubular interstitial 
fibrosis (D). Tubular injury was presented by PAS staining of the tubular area as tubular vacuolization 
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(arrow) and loss of brush border (arrowhead). Data are presented as mean ± SEM. n = 6–14. *P < 0.05 
using Mann–Whitney U test.  
 
 
 
Figure 5: Nephrin expression. (A) A representative image of nephrin immunofluorescent staining and 
(B) quantification of the signal as the percentage of the glomerulus area (n = 5–10). (C) The graphs 
represent the ratio between mRNA expression normalized to the expression of GAPDH mRNA (n = 5–7). 
Data are presented as mean ± SEM. *P < 0.05 using Mann–Whitney U test. 
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Figure 6: Dihydroethidium (DHE) staining (A), quantification of DHE staining (B), and glucose-6-
phosphate dehydrogenase (G6PD) mRNA expression (C). DHE staining quantification was performed 
in 5 samples in each group. (A) The DHE positive staining showed as red fluorescent staining on the cell 
nucleus on glomerular (G) and tubular (T) area. (B) Quantification of DHE staining intensity. (C) The 
graphs represent the ratio between G6PD mRNA expression normalized to the expression of GAPDH 
mRNA (n = 6–11). Data are presented as mean ± SEM. *P < 0.05 using Mann–Whitney U test. 
 
 
